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Abstract
Purpose
Recall by genotype (RbG) research recruits on the basis of genetic variation. Increased use
of this approach presents an ethical conundrum for cohort studies/biobanks: whether to
inform individuals of their genetic information and deviate from standard practice of non-dis-
closure of results, or mask this information at the level of the individual participant. This
paper examines the perspectives of research study participants on RbG research.
Methods
Fifty-three semi-structured interviews were conducted with young adult participants of the
Avon Longitudinal Study of Parents and Children (ALSPAC). Topics included understand-
ings of RbG research, expectations around recruitment and communication of research
findings.
Results
Participants uniformly expressed a deep trust and faith in ALSPAC and considered them-
selves part of the ALSPAC team. Such perspectives, alongside a limited knowledge of
genetics and modest interest in reported research outcomes, meant few participants
reported immediate concerns about being recruited by genotype.
Conclusion
Our findings highlight the responsibility and duty of care on RbG researchers, and longitudi-
nal studies more generally, and the importance of solidarity, reciprocity and co-production in
study-participant relations. As such, we consider existing recommendations for conducting
RbG research in longitudinal studies in light of our results and speak to recent changes in
the approach used by ALSPAC.
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Introduction
Recall by genotype (RbG) studies recruit prospective participants on the basis of genetic varia-
tion of interest. This contrasts with more established genetic research methodologies such as
genome wide association studies (GWAS), where participants are selected to be representative
of specific populations or on the basis of particular phenotypes. The likelihood of participants
carrying the genetic variation of interest depends upon the frequency of that variant(s) and the
predictability of phenotype manifestation (penetrance). The GWAS approach can be an ineffi-
cient and potentially costly recruitment mechanism for rare diseases variants or low frequency
variants relevant to common diseases. RbG studies target individuals (or their samples) who
have already undergone genotyping. This type of design is able to achieve equivalent biological
exposure (i.e. to capture balanced numbers of specific gene variants) and analytical power in a
relatively small number of participants as a result of the availability of large pre-genotyped col-
lections. This approach can be effective in dissecting genetic association signals through deep
phenotyping in smaller sample sets; it is a cost effective strategy and in the rare variant setting
it may be the only feasible approach to recruitment for novel studies or for replication studies
[1,2].
RbG studies, however, present novel ethical context and challenges. If participants are to be
fully informed of the structure of an RbG study, including naming the variant(s) of interest,
then inadvertent disclosure of genetic information during the recruitment process is possible
and with it the potential to heighten anxiety among participants about their health status, espe-
cially if a variant is implicated in serious or stigmatising conditions. The ethical principle of
autonomy (the basis of informed consent in contemporary research) is pitched against the
‘right not to know’ and the principle of non-maleficence (the precept to do no harm) [3]. This
central tension in RbG research (also termed Genotype Driven Recruitment/GDR) has been
identified [4–6] in studies involving biobanks and other repositories that include participants
with genotypic data collection, including disease and tissue-based biobanks [7–9], population-
based biobanks7 and collections based on health records or direct-to-consumer testing [10].
While such studies have been careful not to conflate the issues of return of clinically useful
findings (incidental findings) with disclosure of genetic information through recruitment,
they point to a range of cognate issues that bear consideration: the need to avoid participant
anxiety if the genetic information–or re-contact itself–is unexpected [4,11]; the possibility that
even uncertain information may be important to participants [9]; the potential for over-target-
ing of rare conditions and thereby potential stigmatisation of such groups; and, the challenge
that informational utility includes personal utility and personal meaning as well as clinical util-
ity, especially where there is parental, familial or personal experience of disease [7–9,11]. As a
counter to these potential harms, are the harms of not pursing the advancement of science
through such methods, identified as a human right under Article 27 of the Universal Declara-
tion of Human Rights, i.e. the right “to share in scientific advancement and its benefits” [12].
Empirical studies with participants of disease-based biobanks have also demonstrated par-
ticipant solidarity [13] with research and researchers, and perceived co-production [14] of
research outcomes. Participants, having had long-term relationships with their health care
providers and researchers (who may have been one in the same), often felt part of the ‘team’
working towards discoveries and treatments for themselves, their families and the community
affected by a disease [7,9]. Conversely, population-based biobank participants have been
shown more likely to be anxious about the disclosure of unexpected genetic information [7].
Seven broad recommendations for RbG have been proposed through research participant
interviews (mostly disease-based biobank participants), a survey of IRB Chairs and a consen-
sus workshop [15]. While useful and important, these recommendations are context specific
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and do not work for all circumstances [10]. As noted by Olson and colleagues, guidelines are
needed for “all the varied circumstances under which genetic data may become available for
researchers” [6]. To this end, we examined what we describe as the ethical conundrum facing
RbG studies in the context of a longitudinal birth cohort, the Avon Longitudinal Study of
Parents and Children (ALSPAC).
ALSPAC is a “transgenerational prospective observational study investigating influences on
health and development across the life course” that includes repeated deep phenotypic data
and biosample collection, with whole genome sequencing on a subset of the cohort [16]. Par-
ticipants comprise a cohort of offspring born to pregnant women recruited between April
1991 and December 1992 in Bristol, UK, their parents, grandparents, siblings and most
recently their own offspring [16]. The birth cohort (now young adults) are also referred to–
and frequently refer to themselves–as Children of the 90s (Co90s). Alongside their families,
participants have been followed through a series of ongoing data collection time points involv-
ing questionnaires and clinical assessment. Sub-studies involving smaller samples are ongoing,
including RbG studies. In all sub-studies it is ALSPAC administrators who circulate invitations
to existing participants on behalf of research teams within and beyond ALSPAC, with invites
arriving on Co90s letterhead signed by ALSPAC principal investigators.
Measures are taken to ensure cohort participants are not overburdened with study invita-
tions. To conduct research involving cohort participants, sub-study researchers work with
ALSPAC administrators to ensure all recruitment materials meet established standards and
protocols. Following the principles and methodologies of Responsible Research and Innova-
tion [17,18], ALSPAC participants are engaged in the approval processes for all research con-
ducted within ALSPAC and take part in governance decisions. Each study application is
reviewed by the Original Cohort Advisory Panel (OCAP), a committee of ALSPAC partici-
pants who provide input and advice on study design, methodology and acceptability based on
their expertise as participants. Study applications are then submitted to the ALSPAC Ethics
and Law Committee (ALEC) for final approval. ALSPAC participants comprise half the mem-
bership of the ALEC, which is currently chaired by a parent participant and deputy chaired by
one of the Original Cohort. It was previously chaired by one of the authors (MJM).
Genome-wide common single nucleotide polymorphism data are now available for over
18000 cohort participants, including a sub-sample of approximately 1800 participants for
whom there is complete genome sequencing [19]. Since 2010, RbG studies of genetic variants
associated with topics such as sleep, body mass index (BMI) [20], schizophrenia, smoking
behaviour and platelet function [21] have been conducted in ALSPAC. ALSPAC maintains a
general principle that biomedical information is not disclosed to cohort participants unless
there is clear evidence that the benefits outweigh the risks and that three conditions are met:
(1) data provide clear, unequivocal evidence of an existing or future health problem; (2) said
health problem is amenable to treatment of proven benefit; and (3) the participant has indi-
cated in advance a wish to be informed if such a problem is identified [22]. The method and
nature of RbG studies is fully described in ALSPAC recruitment documents but specific
genetic variation(s) are not communicated to potential participants.
With no available empirical evidence of the views of the wider ALSPAC participant popula-
tion, we undertook a qualitative study of participant perspectives on the recruitment of cohort
participants into RbG research and the possible receipt of individual genetic information.
ALSPAC participants are well placed for RbG studies because they have already been recruited,
contact is straightforward and many have already given consent for genetic data to be used for
future research. Our study sought both to contribute empirical consideration of RbG recruit-
ment from participants’ perspectives to the scientific literature generally and improvements in
specific local ALSPAC governance of the research it approves and undertakes.
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Methods
Ethics
Ethical approval for this qualitative study was obtained from the Avon Longitudinal Study of
Parents And Children, Law and Ethics Committee, University of Bristol (ALEC) (approval ref-
erence no. 13341).
Recruitment and data collection
A purposive sample (i.e. a non-probability sample of participants based on our research objec-
tives) was generated across three categories: (1) general ALSPAC cohort participants who had
never participated in an RbG study; (2) participants who had participated in an ALSPAC RbG
study; and (3) individuals who had served on one or more ALSPAC committees at which RbG
study applications were discussed (e.g. ALEC, OCAP). In May 2016, study invitations were
mailed to 200 ALSPAC participants (S1 Table), of whom 74 returned expression of interest
forms. Each respondent was followed up at least twice to arrange an interview date and time;
21 did not reply to follow up or were unable to schedule an interview within the data collection
timeframe (June to August 2016). The final response rate (26.5%) is reflective of the often
mobile and changeable circumstances of these young adults as they transitioned between edu-
cation and work. All participants who were able to attend an interview (in person or by phone/
Facetime/Skype) within the data collection timeframe were included. Interviews continued
beyond the point of saturation(the point at which no new themes were forthcoming) [23] in
each of the three sub-groups. Our decision to continue interviewing was based on an ethical
commitment to respect participants’ wishes to be included as well as a methodological oppor-
tunity to evaluate our assessment of saturation. Once we had concluded that no new themes
were emerging, important issues were re-emphasised in the latter interviews and additional
negative cases (contrasting examples) were elicited. In total, 53 semi-structured interviews
were conducted. In keeping with established ALSPAC practice, participants each received a
£20 gift voucher and were reimbursed for travel costs where applicable. An interview topic
guide was developed, approved by the ALEC, and revised iteratively throughout the interviews
[23] (S2 Table). Feedback was also solicited on a leaflet distributed with the invitations explain-
ing the principles of RbG research [24]. Interviews were conducted by two of the authors (FB
(n = 20) and JTM (n = 33)), lasted between 14 and 62 minutes, and were audio-recorded and
transcribed verbatim with participant’s consent. Resultant transcripts were checked for accu-
racy and anonymised.
Methodology and epistemic framework
This paper provides an example of empirical ethics; that is, it is a consideration of ethics based
on primary research rather than argumentation drawn from ethical, legal or other normative
principles. Empirical ethics, as any research, may be based on a variety of epistemic or method-
ological assumptions. We take a moment here to describe those roots so the reader is better
placed to judge our interpretations and interpret our findings. The methodology used for this
study was constructivist interpretivist: “particular actors, in particular places, at particular
times, fashion meaning out of events and phenomena through prolonged, complex processes
of social interaction involving history, language and action” and “that to understand this
world of meaning one must interpret it” [25]. Following Mol [26,27], we also start from a
premise that the individual subject of ethical consideration is multiple rather than singular or
plural. The research participant imagined for informed consent is typically an autonomous,
rationale, choosing individual who will, with sufficiently accurate and unbiased information,
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make decisions about their involvement in research based on their preferences and values.
This is not so much an untrue description as it is overly simplistic for analytic purchase. A
research participant might instead be considered plural, holding different perspectives based
on background and experience that in turn shape that person’s values, preferences and deci-
sions. But Mol argues that as persons we inhabit many possible personhoods: we can be both
parent and child, teacher and learner, leader and team member. Indeed, we may be all of these
persons (or subjects) in different settings. Each different way of being a person (or subject) is
shaped by what we expect to do or be and by what is expected of us. We can see these as being
different subjects, or, less ontologically confronting, as persons taking on different subject
positions inhabited based on circumstance and which are situated and relational; that is, they
occur in specific social and geographic settings and in relationships with other persons.
While there is much in common, there is an important distinction between understanding
the world as inhabited by plural or by multiple subjects. Seeing the subject as plural under-
stands individuals whose views may differ from one another but for whom there is an internal
coherence of perspective. Seeing the subject as multiple understands individuals as each poten-
tially inhabiting many possible subject positions, at different moments and in different set-
tings. For the purposes of analysis here, we consider our research participants as capable of
holding more than one subject position and that these are not always apparently or necessarily
coherent. This is the epistemic basis for the interpretations we make of the data collected; as
such, our approach is a necessarily constructionist rather than realist epistemology.
Data analysis
Interviews were coded thematically using the constant comparative approach [23] and follow-
ing the steps provided by Braun and Clarke [28] for organising analysis without imposition of
a specific epistemic framework. This approach involves researchers familiarising themselves
with the data corpus (e.g. the interview data in this study), generating initial codes and then
developing, reviewing and defining themes. Having identified our themes using this approach,
we undertook an interpretive analysis of them based on the epistemic framework outlined ear-
lier. The findings presented here are necessarily one of a number of possible interpretations;
that is, ours is not a post-positivist analysis that assumes a singular interpretation [29]. Nor is it
exhaustive: the wealth of data collected in qualitative research enables multiple questions to be
posed [29]. In order to warrant our interpretations, we present verbatim extracts from the data
and offer thick descriptions [30] of these interpretations to enable the reader to judge the
soundness of our interpretations [31]. We also undertook to enhance the quality and credibil-
ity of our analysis following Patton [32,33] by testing rival explanations, searching for negative
or disconfirming cases, triangulating through multiple analysts, and challenging the credibility
of the researcher(s).
This epistemic framework and deep familiarisation with the interview data (which included
listening to the audio recordings throughout the data collection period) allowed the authors
(JTM, FB, MJM) to revise the topic guide iteratively and provided the basis for them reaching
decisions about saturation. To allow FB to complete the requirements for a Master’s research
project, she conducted and coded 20 of the first 21 interviews, identifying and exploring pre-
liminary themes under the direction of MJM and FB’s project supervisor (see Acknowledg-
ments). This work was completed prior to data analysis of all 53 interviews for this paper,
which involved JTM, FB and MJM familiarising themselves with the data by repeatedly and
independently reading all of the transcripts and listening to the audio-recordings. Then, based
on joint discussions among all three, JTM developed a coding frame for analysis and coded the
transcripts using NVivo 11 software. MJM undertook additional checks on coding and
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interpretation. The results were considered in relation to FB’s earlier work and as such offered
a means to assess inter-rater reliability. Throughout the main analytic process, disconfirming
cases (instances where participant perspectives ran counter to the developing interpretations)
were sought to challenge emergent constructs, evaluate alternate explanations and refine resul-
tant interpretations. Lastly, the final text was reviewed against the coded data to ensure accu-
racy. In keeping with standard qualitative practice, brief excerpts of participants’ comments
are provided in support of our analytic findings. All individuals quoted were pseudonymised
specifically for this paper, nominated alphabetically throughout and indicative of gender only.
To protect participant confidentiality, the qualitative data in this study are accessible through
managed access under the ALSPAC Access Policy, Version 8.0, May 2018. These restrictions
form part of the ethical agreements made with study participants and approved by the Avon
Longitudinal Study of Parents And Children, Law and Ethics Committee, University of Bristol
(ALEC) (approval reference no. 13341). Applications for access should be made to the
ALSPAC Data Access Committee through its online portal: https://proposals.epi.bristol.ac.uk/.
Information about the ALSPAC Access Policy and process is available at (http://www.bristol.
ac.uk/alspac/researchers/access/).
Results
Of the 53 participants interviewed, 29 were female and 51 has been enrolled in ALSPAC con-
tinuously since birth. We include no further participant characteristics in order to maintain
the privacy of the individuals involved. This paper identifies three key participant perspectives
about recruitment, the return of research results generally and the return of results in relation
to RbG research in particular.
Perspectives on participation
Participants all reported very high levels of trust and engagement in both the administration
and scientific goals of the ALSPAC project. They frequently expressed satisfaction at having
played an important role in the advancement of medical research and discovery of new treat-
ments. When asked how they decided whether to accept new research invitations from
ALSPAC, almost all reported their default choice was to participate. Many also indicated they
gave only limited consideration to the research topic under consideration or the information
provided in recruitment documents.
Because I’ve been part of Children of the ‘90s all my life, I kind of just don’t really think about
it. I just do it. It’s just part of something that I do now. I tend to just do whatever I can to help,
really, because it’s such a big study and they’ve found out so much information that I think if I
can help then, yeah, so I just do it. [Alice]
Few participants could recall having declined a study invitation. Where they could, only
two reasons were given: practical barriers (e.g. time restrictions; geographical distance) or per-
sonal dislikes (e.g. drawing blood; breast examinations).
Overall, participants expressed limited interest in knowing why they had been invited.
While most did not feel it was important to know the reason for their recruitment, a few indi-
cated such information could be interesting, though not knowing would not deter
participation.
I’m not too bothered about why. It’s sometimes nice to know just out of interest, but it wouldn’t
influence whether I said yes or no. [Belinda]
The ethics conundrum in RbG research
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A few participants identified concerns around participation in research, either ‘front end’
issues (e.g. gauging potential risk; agreeing with a study’s aims) or post-study concerns (e.g.
potential return of unwelcome adverse findings). Again, such concerns were almost never
expressed as barriers to participation.
I mean there is always that worry that, you know, something might be wrong with you and
you might never find out even if all the data is collected. I guess I would be upset to find out
later that I had some kind of terrible disease which I could have known about if I had been told
why I was invited to something. [Cathryn]
Many participants used their established trust and faith in ALSPAC to ‘shorthand’ deci-
sion-making about recruitment. Participants also frequently blurred any distinction between
ALSPAC data collection events (known as Focus Days) and sub-studies conducted by outside
researchers. This finding did not lead us to conclude that participants were unable or unwilling
to think critically about recruitment and participation; rather, we found most simply did not
perceive a need to do so. The exception were participants who had served on ALSPAC panels
and committees. While equally expressive of trust and faith in ALSPAC, these individuals
appeared to engage more thoroughly with study invitations, even if their decision to participate
was similar to other participants.
Perspectives on genetics
While our study did not measure participants’ knowledge of genetics, the interview data sug-
gested most had a basic high school level of understanding, with a smaller number either quite
knowledgeable or largely uninformed. Participants typically found the level of explanation in
an ALSPAC leaflet about RbG research [24] (written at high school level knowledge and
included with the study invitations) was accessible and would likely be so for other cohort par-
ticipants. Where individuals reflected on genetics in their interviews, they typically used termi-
nology expressing curiosity or interest (I’d just love to know really what’s different about me
and how that maybe affects me compared to other people. [Deborah]) or perceived certainty
(Your DNA is essentially what you are built of. There is no escaping your own DNA. [Edwin]).
Given the iterative nature of the interview process, only the final 14 participants were asked
specifically how much they reflected on their genetic make-up in everyday life. Few reported
doing so to any extent; personal genetics was expressed more as a “backburner thing” [Fred] of
limited interest. In itself, this finding was not surprising since the participants’ age and general
circumstance (i.e. mid-20s, still establishing careers and personal relationships) would not sug-
gest any pressing need to reflect regularly on genetics. The perspective of one participant–a
new parent–did hint, however, that this could change.
To be honest, I never used to really think about [my genetic make-up]. However, I do think
about it more now. It’s something that, obviously with my little one, it’s something that you do
think about and you do kind of wonder how it all works. [Alice]
As regards genetics and RbG research, few participants besides those who had served on
ALSPAC panels and committees indicated much knowledge of this recruitment technique.
Because over half of our sample involved individuals who had already participated in an
ALSPAC RbG study, this finding illustrated the known tendency of research participants to
forget the details of research in which they are involved, specifically the information in consent
forms and participant leaflets [34,35]. This may also suggest, however, that previous ALSPAC
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recruitment materials could have been even more clear and concise (even though these had
been reviewed by participants in advance).
RbG research as discussed was generally seen in either positive or neutral terms (“a lot more
efficient” [Fionnuala]; “just another study” [Georgina]). Few participants felt their decision to
participate would be influenced by knowing they had been invited based on a genetic varia-
tion. Those who thought it might be also stated such information could make them more likely
to enrol. The authors caution against interpreting this finding as evidence of unconditional
acceptance of RbG research because some participants also incorporated suggestions of unease
or hesitation into their observations of genetics-based research. For example, when asked to
reflect on possible disadvantages of RbG research, one participant observed:
I suppose [RbG studies] might reveal things that people don’t want to know, including negative
outcomes. I suppose people don’t want to know that. [Joanne]
Another individual who knew she had already participated in an RbG study expressed
ongoing concerns:
I still think about it now because I still think–I guess I would have liked–I’m someone who
would have liked to have known which group [I was in]. But there’s no way of telling me
because then it would affect the study if I knew or it could affect it. But I still think, “Oh, I won-
der which group I was part of?” because I wasn’t actually told. [Heather]
While participants largely reported being unconcerned about RbG research, experiences
such as Heather’s could increase as RbG recruitment becomes more common. Though not yet
evident among our participants at their life stage (excepting the one parent-participant), if
cohort participants begin to reflect more critically about on their genetics (e.g. once they have
or are planning to have children) this may change. Individuals who once saw little reason to
question involvement in RbG studies might develop a stronger interest in doing so.
Perspectives on the return of research results
There was near universal awareness and acceptance of ALSPAC’s practice to return biomedical
information to cohort participants only under the general principles discussed earlier. Partici-
pants expressed little expectation they would receive information about themselves.
I’ve never questioned it [information provision in ALSPAC] because sometimes you’ll
come away and you’ll have nothing or they can give you a scan or something and it’s nice
to come away with something. But I suppose it’s not about me. I mean, it’s more about
the overall picture. So, I never expect to receive anything. It would be really interesting but
I understand it’s such a large scale thing that they couldn’t, you know, analyse everyone
and give everyone individual feedback, and I understand that, so it’s not a thing [laughs].
[Isabelle]
Such data led us to conclude that ALSPAC’s non-disclosure policy was widely accepted for
three reasons: it had been communicated repeatedly and clearly; individuals trusted ALSPAC
to act if significant and remediable results were found; and participants viewed their role in
ALSPAC primarily as data providers. Regarding communication of research findings more
generally, most participants reported being only moderately interested in the outcomes of
ALSPAC studies and were happy to receive such information via occasional newsletters.
When presented with the possibility of using technology to ‘push’ personalised digests of
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findings of specific interest (e.g. asthma), few saw much appeal. Similarly, there was little inter-
est in receiving routine individual results (despite many participants recalling fondly having
received souvenir copies of scans and such as children).
While our participants did not generally express any strong concerns about the return of
research information, the authors did identify two matters of note. First, ALSPAC was very
much expected to observe its current policy. Participants articulated this expectation either as
an ethical obligation or as a benefit arising from being a cohort member. This was a general
expectation and not restricted to RbG studies or genetic information.
I went to my last Focus group [a routine data collection point, not an RbG study] and then I
got a phone call from the [ALSPAC] doctor a week later because my blood results weren’t quite
right. And they advised me to go to the doctor’s and have a repeat. And it was all fine in the
end, but I think that was really good of them to call me–to let me know–because if I hadn’t
have gone to Children of the 90s and hadn’t had that blood test, then it might have been some-
thing more serious and then I would have never have known about it. [Jackie]
The second concern noted among participants about the return of information related spe-
cifically to RbG research. During the interviews individuals were presented with a hypothetical
scenario in which an RbG study identified a link between a genetic variation and an increased
likelihood of developing type 2 diabetes in middle age. Most participants felt ALSPAC had a
duty to tell them both the outcome of such a study and whether they personally carried the var-
iation in question (either at the time of recruitment or following the study). The reasons cited
turned less on ethical obligation or participatory benefit and more on a belief that health
threats in the future might potentially be mitigated through behaviour change.
To be honest, I don’t know much about . . . type 2 diabetes, so if it was possible for me to pre-
vent it by controlling my external factors then, yes, they should let me know. I mean, I think
either way, yes, they should let me know. But if there was a way to prevent it, then it’s more
important for them to let me know so I could do something about it and I’d have more control
over it. [Katy]
Finally, participants were asked to consider the relative cost of returning individual results,
especially given an anticipated increase in RbG research. While individuals expected ALSPAC
to return adverse findings of clinical significance (such as the hypothetical study on type 2 dia-
betes), most preferred funds be spent on research if the mechanics of returning results proved
too costly.
. . .in an ideal world we’d get both, so without having to take any budget or resources from the
study or publication of research and be able to bring in counsellors or whatever, and be able to
relay that information back on to me, that would be the ideal world. But if it’s not the case and
it’s not feasible–if it’s not financially viable–then I wouldn’t have any gripes, I suppose. It
wouldn’t stop me from wanting to do the study. [Liam]
This finding suggested that participants’ perspectives on the return of results could become
more complex and dynamic as the number of RbG studies increases. Such a change might
challenge current ALSPAC policy on returning results if participants situate the health conse-
quences of such findings far enough into the future that individuals feel they can effect change
and prevent negative outcomes. In such a situation, cohort members may no longer be willing
to prioritise research over returning results.
The ethics conundrum in RbG research
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Discussion
Our study demonstrated that participants’ perspectives on RbG research could only be fully
understood within the context of their long term and ongoing experience within ALSPAC.
Capturing perspectives on RbG research required acknowledging the expertise participants
had acquired as data providers over 20+ years and the impact their relationship with ALSPAC
has had on engagement with the research. Like Michie’s [8] Cystic Fibrosis patient partici-
pants, ALSPAC participants demonstrated societal solidarity [13], seeing themselves as con-
tributing to a greater good. They also understood this contribution to be reciprocal:
participants appreciated learning something about themselves and expected ASLPAC to act in
their interests as the need arose. Our results underscore the importance of learning from the
experience of study participants when addressing emergent governance challenges posed by
new methodologies. Although participants in our study seemingly expressed limited interest
in knowing the reasons for their recruitment or the findings of research, their attitudes spoke
to both the ongoing advantages and limitations of their close working relationship with
ALSPAC. Indeed, the strength of trust in ALSPAC’s ‘duty of care’ role provides an important
understanding, namely that any such perception or expectation arguably confers on the study
a higher responsibility towards its participants than in a study where engagement is less strong.
Despite an explicit commitment by ALSPAC not to over-burden participants, such factors
could leave participants potentially vulnerable to over-recruitment or foster a default willing-
ness to consent. Moreover, in early 2018 ALSPAC introduced a two-step approach to address
some of ethical challenges when recruiting for RbG studies. This change was developed by
working with participants and members of the ALEC and was undertaken cognisant of this
study’s findings. The new approach recognises that there can be sensitivity through invitation
alone to an RbG study and that ALSPAC would not knowingly disclose information about
individual carriage of a genetic variation during the recruitment process. All participants are
being contacted to communicate the particulars of RbG research and to explain how genetic
risk works. This is being accomplished using the leaflet included in our study [24]. Participants
are then being asked whether they are in principle open to receiving invitations for this type of
research; those who are not can then opt out.
While the ethical issues facing RbG research are closer to those of population-based genetic
research than family studies [36], such an approach is inextricably linked to the issue of dis-
closing individual results [4]. There is undoubtedly a distinction between genetic data of clini-
cal utility and data commonly used in epidemiological research, but differences in the
implications of such categories for informed consent and ethical study conduct are often
blurred [37]. Where a variant is associated with a serious or stigmatising condition, a decision
is needed about whether it is in the best interests of potential participants to conceal that con-
dition. This decision cannot be made without the input of participants themselves, either
through their routine involvement in study governance or through empirical studies such as
this one. But such input must not be deemed sufficient for all time: participants’ perspectives
and needs are dynamic and can evolve. In a project with strong participant engagement, par-
ticipants must be engaged fully in the determination of what counts as open communication
and the value of individual genotype disclosure.
We have attempted in this paper to contextualise the central tension between avoiding the
possibility of participant harm through revealing unwanted or misunderstood information,
and avoiding deception when explaining recruitment into RbG studies [15]. To date only a
limited number of studies have attempted to assess the effects of incorporating genetic infor-
mation in intervention designs [38,39]. While some studies demonstrated the strong social
and cultural determinants of those influences in the face of information about genetic
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susceptibility [40], evidence on the impact of using genetic data within recall studies is lacking.
Given the qualitative nature of this study, the analytic conclusions drawn are situationally gen-
eralisable to other longitudinal birth cohort studies like ALSPAC. Beyond this, our findings
are theoretically generalizable [41,42]; parallels may be drawn more widely in relation to ethics
practices and RbG research, at least until further empirical work has been reported. For exam-
ple, population-level biobanks such as UK Biobank and the All of Us study face ethical conun-
drums similar to those examined in this paper. Although population-based biobanks may not
be centred around a common experience in ways which have been shown to produce feelings
of solidarity in disease-based biobanks [8] other aspects of solidarity and co-production may
be present; participants in all longitudinal research pass through shared life milestones and
developmental stages. Our findings suggest that whether recruited at birth or in adulthood,
some individuals may come to identify strongly with their study and see themselves as part of
the research team, particularly as participant engagement initiatives become more common-
place. We argue that there are already common expectations for truthfulness and the option to
be told (or not) of critically important information like incidental findings. What remains to
be determined is whether there exists a sliding scale of expectation by study type about what is
communicated upfront or fed back post-study.
Seven recommendations emerged from a consensus workshop about recruitment to studies
based on genotype [15] offering a good starting point for other studies. All were followed by
ALSPAC: (1) participants be made aware of potential for re-contact; (2) participants have a
choice about whether to be re-contacted; (3) re-contact be made by a known person or entity;
(4) recruitment be based on the biobank’s own processes; (5) thresholds for the return of inci-
dental findings be considered differently to the return of genetic information during recruit-
ment; (6) genetic research information offered in the context of RbG recruitment should not
leave participants uninformed about the study’s purpose; and (7) approaches to RbG recruit-
ment be determined in consultation with ethics committees [15]. Our study highlights how
such recommendations are best seen as reflective of one point in an evolving, iterative relation-
ship between a longitudinal study and its participants, one impacted regularly by shifting social
norms and technological advances. Such a perspective is particularly true of the sixth recom-
mendation, which must be tempered by the nature of the condition associated with a variant
(e.g. treatability, stigmatisation), and the seventh recommendation, which is better expanded
to include participants as well as ethics committees.
Furthermore, studies like ALSPAC that have a strong engagement ethic must continue to
engage not only researchers and ethics committees but also their participants, who hold a sepa-
rate and unique form of expertise. ALSPAC can draw not only from its ethics committee but
from its participant panels and qualitative studies such as this one. Between them, innovative
approaches can be developed to provide information to participants in formats offering multi-
ple levels of explanation; advance creative mechanisms for communicating information on
increasingly complex topics; and offer opportunities for participants themselves to explore and
critique the ethical implications of new study designs. Studies such as ALSPAC must be mind-
ful that in the context of a strong and established study-participant relationship, the inclination
of participants can be to decide first and ask questions later when considering study invita-
tions. Attention to such understandings will underpin governance practices and help ensure
they remain fit for purpose. Governance practices which centrally include participants in deci-
sion making processes are, arguably, best suited to developing appropriate, trustworthy and
credible safeguards and oversight of cohort and biobank research.
Limitations of the study. While our findings may be suggestive of perspectives found among
other longitudinal studies, they are not likely transferable directly to other types of biobanks
with one-off collections (e.g. disease or tissue-based biobanks). Our sample was self-selected
The ethics conundrum in RbG research
PLOS ONE | https://doi.org/10.1371/journal.pone.0202502 August 16, 2018 11 / 14
and as such we may have heard disproportionately from individuals interested in the topic
and/or open to discussing a potentially sensitive subject matter. Nonetheless, this empirical
study demonstrates that doing so is necessary to understand study participants’ perspectives in
terms of their wider experience of involvement in a biobank.
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